| Year |
Citation |
Score |
| 2022 |
Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, ... ... Shukla SA, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. PMID 35447074 DOI: 10.1016/j.cell.2022.03.033 |
0.306 |
|
| 2021 |
Ouspenskaia T, Law T, Clauser KR, Klaeger S, Sarkizova S, Aguet F, Li B, Christian E, Knisbacher BA, Le PM, Hartigan CR, Keshishian H, Apffel A, Oliveira G, Zhang W, ... ... Shukla SA, et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nature Biotechnology. PMID 34663921 DOI: 10.1038/s41587-021-01021-3 |
0.337 |
|
| 2021 |
Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Shukla SA, Gusev A, Braun DA, Choueiri TK, et al. Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34074656 DOI: 10.1158/1078-0432.CCR-21-0575 |
0.309 |
|
| 2021 |
Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, ... ... Shukla SA, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. PMID 33711273 DOI: 10.1016/j.ccell.2021.02.013 |
0.305 |
|
| 2021 |
Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications. 12: 808. PMID 33547292 DOI: 10.1038/s41467-021-21068-9 |
0.304 |
|
| 2020 |
Trinh A, Gil Del Alcazar CR, Shukla SA, Chin K, Chang YH, Thibault G, Eng J, Jovanovic B, Aldaz CM, Park SY, Jeong J, Wu C, Gray J, Polyak K. Genomic alterations during the in situ to invasive ductal breast carcinoma transition shaped by the immune system. Molecular Cancer Research : McR. PMID 33443130 DOI: 10.1158/1541-7786.MCR-20-0949 |
0.357 |
|
| 2020 |
Bachireddy P, Ennis C, Nguyen VN, Gohil SH, Clement K, Shukla SA, Forman J, Barkas N, Freeman S, Bavli N, Elagina L, Leshchiner I, Mohammad AW, Mathewson ND, Keskin DB, et al. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Science Translational Medicine. 12. PMID 32938797 DOI: 10.1126/Scitranslmed.Abb7661 |
0.328 |
|
| 2020 |
Li Y, Burgman B, McGrail DJ, Sun M, Qi D, Shukla SA, Wu E, Capasso A, Lin SY, Wu CJ, Eckhardt SG, Mills GB, Li B, Sahni N, Yi SS. Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Research. PMID 32855206 DOI: 10.1158/0008-5472.Can-20-0384 |
0.425 |
|
| 2020 |
Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, ... ... Shukla SA, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine. PMID 32472114 DOI: 10.1038/S41591-020-0839-Y |
0.462 |
|
| 2020 |
Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, ... ... Shukla SA, et al. Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunology Research. PMID 32321774 DOI: 10.1158/2326-6066.Cir-19-0866 |
0.446 |
|
| 2020 |
Mahoney KM, Ross-Macdonald PB, Shukla SA, Braun DA, Song L, Veras E, Wind-Rotolo M, Allen EMV, McDermott DF, Hodi FS, Choueiri TK, Freeman GJ. Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer. Journal of Clinical Oncology. 38: 746-746. DOI: 10.1200/Jco.2020.38.6_Suppl.746 |
0.334 |
|
| 2020 |
Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Nassar A, Abou Alaiwi S, Flippot R, Steinharter JA, Nuzzo PV, Ishii Y, Ross-Macdonald P, Lee GM, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI). Journal of Clinical Oncology. 38: 715-715. DOI: 10.1200/Jco.2020.38.6_Suppl.715 |
0.388 |
|
| 2020 |
Ficial M, Jegede O, Sant'Angelo M, Moreno S, Braun DA, Wind-Rotolo M, Pignon J, Catalano PJ, Sun M, Van Allen EM, Freeman GJ, Sharpe A, Hodi FS, Motzer RJ, Wu CJ, ... ... Shukla SA, et al. Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. Journal of Clinical Oncology. 38: 5023-5023. DOI: 10.1200/Jco.2020.38.15_Suppl.5023 |
0.345 |
|
| 2020 |
Braun DA, Hou Y, Bakouny Z, Ficial M, Sant'Angelo M, Ross-Macdonald P, Jegede O, Sun M, Wind-Rotolo M, Pignon J, Neuberg DS, Catalano PJ, Freeman GJ, Sharpe A, McDermott DF, ... ... Shukla SA, et al. Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade. Journal of Clinical Oncology. 38: 5010-5010. DOI: 10.1200/Jco.2020.38.15_Suppl.5010 |
0.461 |
|
| 2019 |
Li B, Zhang H, Liu L, Zhang J, Chen J, Ye J, Shukla SA, Qiao J, Zhan X, Chen H, Wu CJ, Fu YX. Investigation of antigen-specific T cell receptor clusters in human cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31831563 DOI: 10.1158/1078-0432.Ccr-19-3249 |
0.434 |
|
| 2019 |
Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications. 10: 4346. PMID 31554815 DOI: 10.1038/S41467-019-12361-9 |
0.373 |
|
| 2019 |
Braun DA, Ishii Y, Walsh AM, Van Allen EM, Wu CJ, Shukla SA, Choueiri TK. Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. Jama Oncology. PMID 31486842 DOI: 10.1001/Jamaoncol.2019.3158 |
0.326 |
|
| 2019 |
Li S, Sun J, Allesøe R, Datta K, Bao Y, Oliveira G, Forman J, Jin R, Olsen LR, Keskin DB, Shukla SA, Wu CJ, Livak KJ. RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis. Nature Protocols. PMID 31341290 DOI: 10.1038/S41596-019-0195-X |
0.312 |
|
| 2019 |
Pignon JC, Jegede OA, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, et al. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30670497 DOI: 10.1158/1078-0432.Ccr-18-3206 |
0.304 |
|
| 2019 |
Pignon J, Jegede O, Shukla SA, Braun DA, Horak C, Wind-Rotolo M, Ishii Y, Catalano PJ, Freeman GJ, Jennings RB, De Cubas A, Rathmell K, Choueiri TK, Atkins MB, McDermott DF, et al. Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). Journal of Clinical Oncology. 37: 4568-4568. DOI: 10.1200/Jco.2019.37.15_Suppl.4568 |
0.328 |
|
| 2019 |
Alaiwi SA, Nassar A, Bakouny ZE, Berchuck JE, Nuzzo P, Flippot R, Flaifel A, Steinharter JA, Baca S, Margolis C, Vokes N, Du H, Shukla SA, Braun DA, Signoretti S, et al. Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs). Journal of Clinical Oncology. 37: 103-103. DOI: 10.1200/Jco.2019.37.15_Suppl.103 |
0.379 |
|
| 2019 |
Bachireddy P, Ennis C, Nguyen VN, Barkas N, Shukla S, Clement K, Freeman S, Gohil SH, Bavli N, Elagina L, Leshchiner I, Brown JR, Getz G, Ho VT, Neuberg DS, et al. Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL) Blood. 134: 516-516. DOI: 10.1182/Blood-2019-129520 |
0.369 |
|
| 2019 |
Hu Z, Leet D, Sarkizova S, Holden R, Sun J, Klaeger S, Clauser KR, Shukla SA, Zhang W, Carr SA, Fritsch EF, Pentelute BL, Hacohen N, Keskin DB, Ott PA, et al. Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A010 |
0.419 |
|
| 2018 |
Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. PMID 30568305 DOI: 10.1038/S41586-018-0792-9 |
0.406 |
|
| 2018 |
Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, Eisenhaure TM, Pendergraft WF, Hua P, Pham HC, Bu X, Zhu B, Hacohen N, Fritsch EF, Boussiotis VA, et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunology, Immunotherapy : Cii. PMID 30564891 DOI: 10.1007/S00262-018-2282-1 |
0.365 |
|
| 2018 |
Hu Z, Anandappa AJ, Sun J, Kim J, Leet DE, Bozym DJ, Chen C, Williams L, Shukla SA, Zhang W, Tabbaa D, Steelman S, Olive O, Livak KJ, Kishi H, et al. A cloning and expression system to probe T cell receptor specificity and assess functional avidity to neoantigens. Blood. PMID 30150207 DOI: 10.1182/Blood-2018-04-843763 |
0.414 |
|
| 2018 |
Hamada T, Soong TR, Masugi Y, Kosumi K, Nowak JA, da Silva A, Mu XJ, Twombly TS, Koh H, Yang J, Song M, Liu L, Gu M, Shi Y, Nosho K, ... ... Shukla SA, et al. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology. 7: e1442999. PMID 29900052 DOI: 10.1080/2162402X.2018.1442999 |
0.359 |
|
| 2018 |
Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, et al. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. PMID 29656892 DOI: 10.1016/J.Cell.2018.03.026 |
0.398 |
|
| 2018 |
Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, ... ... Shukla S, et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discovery. PMID 29510987 DOI: 10.1158/2159-8290.Cd-17-1327 |
0.465 |
|
| 2018 |
Reardon DA, Neuberg DS, Keskin DB, Tirosh I, Anandappa A, Mathewson ND, Sun J, Shukla SA, Gjini E, Li S, Giobbie-Hurder A, Wucherpfennig K, Suva M, Fritsch E, Rodig S, et al. Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine. Journal of Clinical Oncology. 36: 2020-2020. DOI: 10.1200/Jco.2018.36.15_Suppl.2020 |
0.427 |
|
| 2018 |
Bachireddy P, Barkas N, Shukla SA, Freeman S, Elagina L, Nguyen VN, Clement K, Leshchiner I, Brown JR, Neuberg DS, Ho VT, Soiffer RJ, Ritz J, Getz G, Alyea EP, et al. Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL) Blood. 132: 820-820. DOI: 10.1182/Blood-2018-99-116681 |
0.438 |
|
| 2018 |
Giannakis M, Grasso C, Wells D, Hamada T, Mu XJ, Quist M, Nowak J, Nishihara R, Connolly CM, Shukla S, Grady WM, Wheeler D, Wu CJ, Zaretsky J, Garraway L, et al. Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancer Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Pr03 |
0.52 |
|
| 2018 |
Keskin DB, Tirosh I, Anandappa A, Sun J, Mathewson ND, Shukla SA, Gjini E, Li S, Li L, Giobbie-Hurder A, Le PM, Hu Z, Zhang W, Olive O, McCluskey C, et al. Abstract 5631: Personal neoantigen-targeting vaccination generates neoepitope-specific T cell responses in tumors of patients with glioblastoma Cancer Research. 78: 5631-5631. DOI: 10.1158/1538-7445.Am2018-5631 |
0.424 |
|
| 2018 |
Reardon D, Keskin D, Tirosh I, Anandappa A, Mathewson N, Sun J, Shukla S, Gjini E, Li S, Giobbie-Hurder A, McCluskey C, Chiocca EA, Neuberg D, Wucherpfennig K, Suva M, et al. ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS Neuro-Oncology. 20: vi8-vi8. DOI: 10.1093/Neuonc/Noy148.027 |
0.311 |
|
| 2017 |
Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature Communications. 8: 1136. PMID 29070816 DOI: 10.1038/S41467-017-01062-W |
0.398 |
|
| 2017 |
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. PMID 28988769 DOI: 10.1016/J.Cell.2017.09.007 |
0.4 |
|
| 2017 |
Wang L, Fan J, Francis JM, Georghiou G, Hergert S, Li S, Gambe R, Zhou CW, Yang C, Xiao S, Cin PD, Bowden M, Kotliar D, Shukla SA, Brown JR, et al. Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Research. PMID 28679620 DOI: 10.1101/Gr.217331.116 |
0.466 |
|
| 2017 |
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. PMID 28678778 DOI: 10.1038/Nature22991 |
0.425 |
|
| 2017 |
George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 46: 197-204. PMID 28228279 DOI: 10.1016/J.Immuni.2017.02.001 |
0.427 |
|
| 2017 |
Shukla SA, Howitt BE, Wu CJ, Konstantinopoulos PA. Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. Gynecologic Oncology Reports. 19: 42-45. PMID 28070553 DOI: 10.1016/J.Gore.2016.12.009 |
0.451 |
|
| 2017 |
Lerner SP, Robertson G, Kim J, Cherniack A, Guo G, Akbani R, Kanchi RS, Hoadley KA, Hinoue T, Laird PW, Al-Ahmadie H, Bellmunt J, Castro M, Gordenin D, Mills GB, ... ... Shukla SA, et al. Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. Journal of Clinical Oncology. 35: 4500-4500. DOI: 10.1200/Jco.2017.35.15_Suppl.4500 |
0.459 |
|
| 2017 |
Hu Z, Sun J, Kim J, Anandappa AJ, Leet D, Williams L, Bozym DJ, Chen C, Zhang W, Tabbaa D, Bachireddy P, Shukla S, Steelman S, Keskin D, Wu CJ. Defining the Diversity and Specificity of Neoantigen-Specific T Cells in Chronic Lymphocytic Leukemia Blood. 130: 386-386. DOI: 10.1182/Blood.V130.Suppl_1.386.386 |
0.37 |
|
| 2017 |
Fan J, Wang L, Francis JM, Georghiou G, Hergert S, Li S, Gambe R, Zhou CW, Yang C, Xiao S, Chin PD, Bowden M, Kotliar D, Shukla SA, Brown JR, et al. Abstract 27: Integrated analysis of targeted single-cell genetic and transcriptional heterogeneity suggests novel drivers of chronic lymphocytic leukemia Clinical Cancer Research. 23: 27-27. DOI: 10.1158/1557-3265.Hemmal17-27 |
0.425 |
|
| 2017 |
Miao D, Liu D, Keliher D, Shukla S, Schilling B, Margolis C, Smart A, Garraway L, Hodi S, Schadendorf D, Allen EMV. Abstract 571: Meta-analysis of genomic predictors of response to immune checkpoint therapy in metastatic melanoma Cancer Research. 77: 571-571. DOI: 10.1158/1538-7445.Am2017-571 |
0.443 |
|
| 2016 |
Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, ... ... Shukla SA, et al. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. PMID 27818134 DOI: 10.1016/J.Ccell.2016.10.005 |
0.42 |
|
| 2016 |
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports. 17: 1206. PMID 27760322 DOI: 10.1016/J.Celrep.2016.10.009 |
0.345 |
|
| 2016 |
Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, Dou R, Chen Q, Hodi FS, Choueiri TK, Wu C, Hacohen N, Signoretti S, Liu JS, Liu XS. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nature Genetics. PMID 27240091 DOI: 10.1038/Ng.3581 |
0.486 |
|
| 2016 |
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports. PMID 27149842 DOI: 10.1016/J.Celrep.2016.03.075 |
0.506 |
|
| 2016 |
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, ... ... Shukla SA, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.). PMID 26940869 DOI: 10.1126/Science.Aaf1490 |
0.494 |
|
| 2016 |
Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. PMID 26871470 DOI: 10.18632/Oncotarget.7277 |
0.465 |
|
| 2016 |
Howitt BE, Shukla SA, Konstantinopoulos PA. Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers-Reply. Jama Oncology. 2: 141-2. PMID 26767553 DOI: 10.1001/Jamaoncol.2015.3903 |
0.315 |
|
| 2016 |
Giannakis M, Mu JX, Shukla S, Qian ZR, Cohen O, Nishihara R, Cao Y, Yamauchi M, Sukawa Y, Nosho K, Ng K, Meyerhardt JA, Lawrence M, Gabriel SB, Lander E, et al. Novel driver genes and genomic predictors of immune infiltrates in colorectal cancer. Journal of Clinical Oncology. 34: 557-557. DOI: 10.1200/Jco.2016.34.4_Suppl.557 |
0.507 |
|
| 2016 |
de Velasco G, Miao D, Shukla S, Voss MH, Wu C, Murray B, Meyerson M, Signoretti S, Motzer RJ, Van Allen EM, Choueiri TK. Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 34: 545-545. DOI: 10.1200/Jco.2016.34.2_Suppl.545 |
0.44 |
|
| 2016 |
Miao D, Adeegbe D, Rodig SJ, Shukla S, Amin-Mansour A, Carter SL, Wu C, Wong K, Raut CP, Ott PA, Van Allen EM, Demetri GD, George S. Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation. Journal of Clinical Oncology. 34: 11043-11043. DOI: 10.1200/Jco.2016.34.15_Suppl.11043 |
0.399 |
|
| 2016 |
Wang L, Gambe R, Sun J, Shukla S, Kim J, Brooks AN, Neuberg DS, Fleming MD, Ebert BL, Carrasco RD, Wu CJ. Genome-Wide Analysis of a Novel Murine Model of Chronic Lymphocytic Leukemia Blood. 128: 967-967. DOI: 10.1182/Blood.V128.22.967.967 |
0.423 |
|
| 2016 |
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Fritsch E, Hacohen N, Wu CJ. Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Pr02 |
0.439 |
|
| 2016 |
Li B, Liu T, Wang B, Wang J, Shukla S, Dou R, Hodi S, Wu C, Hacohen N, Liu J, Liu XS. Abstract LB-264: Landscape of tumor-infiltrating T-cell repertoire of human cancers Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-264 |
0.44 |
|
| 2015 |
Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, Stevens J, Lane WJ, Dellagatta JL, Steelman S, Sougnez C, Cibulskis K, Kiezun A, Hacohen N, Brusic V, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nature Biotechnology. PMID 26372948 DOI: 10.1038/Nbt.3344 |
0.586 |
|
| 2015 |
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science (New York, N.Y.). PMID 26359337 DOI: 10.1126/Science.Aad0095 |
0.454 |
|
| 2015 |
Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. Jama Oncology. PMID 26181000 DOI: 10.1001/Jamaoncol.2015.2151 |
0.401 |
|
| 2015 |
Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 160: 48-61. PMID 25594174 DOI: 10.1016/J.Cell.2014.12.033 |
0.428 |
|
| 2015 |
Giannakis M, Shukla S, Mu JX, Nishihara R, Yamauchi M, Sukawa Y, Qian ZR, Nosho K, Inamura K, Bahl S, Ng K, Chan AT, Meyerhardt JA, Gabriel SB, Lander E, et al. Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. Journal of Clinical Oncology. 33: 3505-3505. DOI: 10.1200/Jco.2015.33.15_Suppl.3505 |
0.452 |
|
| 2015 |
Shukla SA, Rajasagi M, Dixon P, Tiao G, Lawrence MS, Sougnez C, Brusic V, Cibulskis K, Kiezun A, Wu CJ, Getz G. Abstract 1093: Sensitive detection of somatic mutations in class I HLA genes reveals enrichment for functional events in cancer Cancer Research. 75: 1093-1093. DOI: 10.1158/1538-7445.Am2015-1093 |
0.553 |
|
| 2014 |
Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS, Thorner AR, de Torres C, Lavarino C, Suñol M, McKenna A, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discovery. 4: 1326-41. PMID 25186949 DOI: 10.1158/2159-8290.Cd-13-1037 |
0.43 |
|
| 2014 |
Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, Cibulskis K, Sidney J, Stevenson K, Ritz J, Neuberg D, Brusic V, Gabriel S, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 124: 453-62. PMID 24891321 DOI: 10.1182/Blood-2014-04-567933 |
0.371 |
|
| 2014 |
Wang L, Shalek AK, Lawrence M, Ding R, Gaublomme JT, Pochet N, Stojanov P, Sougnez C, Shukla SA, Stevenson KE, Zhang W, Wong J, Sievers QL, MacDonald BT, Vartanov AR, et al. Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL. Blood. 124: 1089-98. PMID 24778153 DOI: 10.1182/Blood-2014-01-552067 |
0.43 |
|
| 2014 |
Crompton B, Stewart C, Taylor-Weiner A, Alexa G, Kurek K, Calicchio M, Kiezun A, Carter S, Shukla S, Mehta S, Thorner A, Torres Cd, Lavarino C, Sunol M, McKenna A, et al. Abstract 999: The genomic landscape of pediatric Ewing sarcoma Cancer Research. 74: 999-999. DOI: 10.1158/1538-7445.Am2014-999 |
0.453 |
|
| 2013 |
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, ... ... Shukla SA, et al. The somatic genomic landscape of glioblastoma. Cell. 155: 462-77. PMID 24120142 DOI: 10.1016/J.Cell.2013.09.034 |
0.446 |
|
| 2013 |
Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 152: 714-26. PMID 23415222 DOI: 10.1016/J.Cell.2013.01.019 |
0.406 |
|
| 2013 |
Rajasagi M, Shukla SA, Fritsch EF, DeLuca D, Getz G, Hacohen N, Wu CJ. Tumor Neoantigens Are Abundant Across Cancers Blood. 122: 3265-3265. DOI: 10.1182/Blood.V122.21.3265.3265 |
0.474 |
|
| 2012 |
Quayle SN, Chheda MG, Shukla SA, Wiedemeyer R, Tamayo P, Dewan RW, Zhuang L, Huang-Hobbs E, Haidar S, Xiao Y, Ligon KL, Hahn WC, Chin L. Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro-Oncology. 14: 1325-31. PMID 23074196 DOI: 10.1093/Neuonc/Nos246 |
0.331 |
|
| 2012 |
Hammerman PS, Voet D, Lawrence MS, Jing R, Cibulskis K, Sivachenko A, Stojanov P, McKenna A, Lander ES, Gabriel S, Getz G, Imielinski M, Helman E, Hernandez B, Pho NH, ... ... Shukla S, et al. Comprehensive genomic characterization of squamous cell lung cancers Nature. 489: 519-525. PMID 22960745 DOI: 10.1038/Nature11404 |
0.407 |
|
| 2012 |
Chen AJ, Paik JH, Zhang H, Shukla SA, Mortensen R, Hu J, Ying H, Hu B, Hurt J, Farny N, Dong C, Xiao Y, Wang YA, Silver PA, Chin L, et al. STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes & Development. 26: 1459-72. PMID 22751500 DOI: 10.1101/Gad.189001.112 |
0.345 |
|
| 2012 |
Rajasagi M, Keskin D, Kim J, Zhang W, Shukla S, DeLuca D, Sidney J, Brusic V, Neuberg DS, Getz G, Lander ES, Hacohen N, Wu CJ. Systematic Identification of Personal Mutated Tumor-Specific Neoantigens in CLL Blood. 120: 954-954. DOI: 10.1182/Blood.V120.21.954.954 |
0.481 |
|
| Show low-probability matches. |